Genomic Determinants of Response to Alpelisib Plus Fulvestrant in the SOLAR-1 Trial
{{output}}
Background: Approximately 40% of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) have PIK3CA alterations, which contributes to endocrine thera... ...
